A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain (RETRO)

Celgene

Status: Completed

Conditions: Multiple Myeloma

Study type: Observational

Funder types: Industry

Identifiers

NCT03602755

U1111-1215-4398 (Other Identifier)

NDS-MM-002

Details and patient eligibility

About

This is an observational, post-authorization, retrospective, multicenter study (PAS-OD) that will be conducted in approximately 20 centers in Spain. In all cases, only data recorded prior to the date of study start will be collected to ensure its retrospective nature, thus reflecting real clinical practice, avoiding any influence on the physician's clinical practice.

Enrollment: 706 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged ≥ 18 years
• Patients with newly diagnosed MM who were not suitable candidates for ASCT who started anti-myeloma treatment between 2012 and 2016, inclusive.
• Patients who give informed consent before data collection begins.

Exclusion criteria

• Patients who participated in a clinical trial for first-line treatment of MM during the study period.
• Patients who are alive, but do not give their IC.
• Patients with MM who did not receive treatment.

Trial design

706 participants in 1 patient group

Patients with newly diagnosed transplant-ineligible MM

Description:

Adult Patients with newly diagnosed MM who were not suitable candidates for ASCT who started first-line treatment for the study disease in a routine clinical practice setting between 2012 and 2016, inclusive.